Reiser Markus
Klinik für Innere Medizin, Klinikum Vest GmbH, Behandlungszentrum Paracelsus-Klinik Marl, Marl, Germany.
Med Klin (Munich). 2009 May 15;104(5):356-62. doi: 10.1007/s00063-009-1074-y. Epub 2009 May 16.
Chronic hepatitis B (HBV) and C virus (HCV) infection can lead to liver cirrhosis, hepatocellular carcinoma and death. Treatment of these worldwide prevalent infectious diseases is subject to intensive research efforts with development of new antiviral substances and optimization of treatment strategies using molecular markers. The goal of HBV and HCV treatment is control and elimination of viral replication, respectively, thereby preventing hepatitis-associated complications. While interferon alpha is used less frequently to treat hepatitis B today, it is still (in the pegylated or albumin-fused form) an essential component of hepatitis C therapy. The growing number of targeted therapies such as new nucleus(t)ide analogs, HCV protease and RNA polymerase inhibitors and other new compounds has added complexity to the treatment of viral hepatitis. This update summarizes the current standard of care as well as new developments in chronic hepatitis B and C therapy.
慢性乙型肝炎（HBV）和丙型肝炎病毒（HCV）感染可导致肝硬化、肝细胞癌和死亡。针对这些全球流行的传染病的治疗，人们进行了大量研究，开发新的抗病毒药物，并利用分子标志物优化治疗策略。HBV和HCV治疗的目标分别是控制和消除病毒复制，从而预防肝炎相关并发症。虽然如今干扰素α较少用于治疗乙型肝炎，但它（聚乙二醇化或白蛋白融合形式）仍是丙型肝炎治疗的重要组成部分。越来越多的靶向疗法，如新型核苷类似物、HCV蛋白酶和RNA聚合酶抑制剂以及其他新化合物，增加了病毒性肝炎治疗的复杂性。本综述总结了慢性乙型肝炎和丙型肝炎治疗的当前护理标准以及新进展。
